Trial reportJournal of blood medicine2026
A Clinical Investigation of Hypoxic Red Blood Cell Administration in Patients with Transfusion-Dependent Hematological Malignancies and Burns.
Trial report in Journal of blood medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Red blood cell (RBC) transfusion is frequently given for patients with chronic anemias or acute bleeding after injury or surgery. A CE mark-certified and Food and Drug Administration authorized storage system (Hemanext ONE Patients and Methods: The primary outcome was the number of patients who experienced an adverse event (AE) within 24 hours of transfusion and overall up to 7 days (±1 day) post-transfusion. Secondary outcomes included changes in hemoglobin (Hb) levels post-transfusion. Results: Twenty patients (10 with hematological malignancies, 10 with surgical bleeding during burn excision) aged 27-96 years were included (17 males; 8 with hematological malignancies, 9 with burns and 3 females; 2 with hematological malignancies, 1 with burns). All patients in the hematological malignancies group received 2 units of hypoxic RBCs. Patients in the burn group received a mean ±standard deviation (SD) of 1.8 ±0.4 units of hypoxic RBCs. No AEs related to hypoxic RBC transfusion were reported. The mean ±SD changes in Hb from baseline to 15-60 minutes post-transfusion were 1.2 ±0.5 g/dL (hematological malignancies group) and 0.3 ±1.0 g/dL (burn group). Conclusion: This cohort analysis showed that transfusion with hypoxic RBCs processed with the Hemanext ONE storage system was safe and well tolerated in both cohorts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.